Novartis | NOVN - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
AbbVie USD 14.39B 1.85B 2026-06
Alcon AG USD 1.69B 175M 2026-03
Almirall EUR 429.87M 180.02M 2025-12
Amgen USD 5.87B 1.02B 2026-03
AstraZeneca USD 12.86B 251M 2026-06
Autolus Therapeutics Ltd USD 1.65M 2.69M 2026-03
Bayer EUR 6.33B 1.84B 2026-06
Biogen USD 2.12B 307M 2026-06
Bristol-Myers Squibb USD 9.26B 1.19B 2026-06
Eli Lilly USD 16.22B 301.7M 2026-03
Fresenius EUR 1.55B 16M 2026-06
Fresenius Medical Care EUR 1.31B 130.98M 2026-06
Genmab DKK 1.07B 240M 2026-06
Gilead Sciences USD 6.8B 1.29B 2026-06
GlaxoSmithKline GBP 6.51B 757M 2026-06
GRIFOLS EUR 704M 84M 2026-06
Hikma Pharmaceutical USD 362.5M 329.5M 2025-06
J&J USD 18.55B 1.31B 2026-06
Lakefront Biotherapeutics EUR 1.68M 898.68M 2026-03
Lonza CHF 1.29B 248M 2025-06
Merck EUR 3.17B 101M 2026-06
Merck USD 12.09B 1.24B 2026-03
Novartis USD 11.24B 1.18B 2026-06
Novartis USD 10.07B 758M 2026-03
Novo Nordisk DKK 64.01B 1.19B 2025-06
Orion EUR 339.9M 85.9M 2026-06
Pfizer USD -248M 11.29B 2026-06
Philips EUR 2.15B 384M 2026-06
Recordati EUR 497.97M 12.85M 2026-06
Regeneron Pharmaceuticals USD 3.71B 778.2M 2026-06
Roche Holding CHF 22.69B 600M 2026-06
Sanofi EUR 8.71B 602M 2026-06
UCB EUR 3.19B 621M 2025-12